BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31889751)

  • 1. Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience from Pakistan.
    Bhatti ABH; Dar FS; Qureshi AI; Khan NY; Zia HH; Haider S; Shah NH; Rana A
    J Clin Exp Hepatol; 2019; 9(6):704-709. PubMed ID: 31889751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma?
    Chen LP; Li C; Wen TF; Yan LN; Li B; Yang JY
    Pak J Med Sci; 2015; 31(4):763-9. PubMed ID: 26430399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma Within or Beyond the Milan Criteria: Comparable Long-Term Outcomes.
    Lee S; Song GW; Kim KW; Kwon JH; Lee SG
    Transplant Proc; 2021; 53(1):92-97. PubMed ID: 33288309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.
    Xiao GQ; Song JL; Shen S; Yang JY; Yan LN
    World J Gastroenterol; 2014 Aug; 20(31):10953-9. PubMed ID: 25152599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond milan criteria.
    Lee EC; Kim SH; Shim JR; Park SJ
    Liver Transpl; 2018 Jan; 24(1):35-43. PubMed ID: 28885774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
    World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
    Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
    Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Analysis after Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Single Center Cohort Study.
    Na BG; Kim SH; Park SJ
    Biology (Basel); 2021 May; 10(5):. PubMed ID: 34065172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
    Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
    Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
    Yoon YI; Song GW; Lee SG; Hwang S; Kim KH; Kim SH; Kang WH; Cho HD; Jwa EK; Kwon JH; Tak EY; Kirchner VA
    J Hepatol; 2018 Jun; 68(6):1153-1162. PubMed ID: 29452208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
    Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
    United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis.
    Liang W; Wu L; Ling X; Schroder PM; Ju W; Wang D; Shang Y; Kong Y; Guo Z; He X
    Liver Transpl; 2012 Oct; 18(10):1226-36. PubMed ID: 22685095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
    Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
    BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living donor liver transplantation for hepatocellular carcinoma.
    Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
    Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).
    Llovet JM; Pavel M; Rimola J; Diaz MA; Colmenero J; Saavedra-Perez D; Fondevila C; Ayuso C; Fuster J; Ginès P; Bruix J; Garcia-Valdecasas JC
    Liver Transpl; 2018 Mar; 24(3):369-379. PubMed ID: 29140601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Living Donor Liver Transplantation for Hepatocellular Carcinoma within Milan Criteria in the Present Era.
    Yoshizumi T; Harimoto N; Itoh S; Okabe H; Kimura K; Uchiyama H; Ikegami T; Ikeda T; Maehara Y
    Anticancer Res; 2016 Jan; 36(1):439-45. PubMed ID: 26722079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma.
    Ninomiya M; Shirabe K; Facciuto ME; Schwartz ME; Florman SS; Yoshizumi T; Harimoto N; Ikegami T; Uchiyama H; Maehara Y
    J Am Coll Surg; 2015 Mar; 220(3):297-304.e3. PubMed ID: 25617912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.